A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label
Public ClinicalTrials.gov record NCT02318368. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Randomized, Double-blind Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label
Study identification
- NCT ID
- NCT02318368
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AVEO Pharmaceuticals, Inc.
- Industry
- Enrollment
- 10 participants
Conditions and interventions
Conditions
Interventions
- Ficlatuzumab Drug
- Erlotinib Drug
- placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2014
- Primary completion
- Dec 31, 2016
- Completion
- Dec 31, 2016
- Last update posted
- Oct 21, 2020
2014 – 2017
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSF Fresno | Fresno | California | 93701 | — |
| Torrance Memorial Medical Center | Redondo Beach | California | 90277 | — |
| Boca Raton Regional Hospital Lynn Cancer Institute | Boca Raton | Florida | 33486 | — |
| University of Miami Sylvester Comprehensive Cancer Center Deerfield Beach | Deerfield Beach | Florida | 33442 | — |
| Kaiser Permanente Hawaii | Honolulu | Hawaii | 96819 | — |
| Cancer Center of Acadiana | Lafayette | Louisiana | 70503 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Valley Medical Group | Paramus | New Jersey | 07652 | — |
| Queens Hospital Cancer Center | Jamaica | New York | 11432 | — |
| Aultman Hospital | Canton | Ohio | 44710 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| UPMC Cancer Center Cancer | Pittsburgh | Pennsylvania | 15232 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02318368, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 21, 2020 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02318368 live on ClinicalTrials.gov.